UPenn
The South San Francisco-based startup recently published two studies showing the performance of its tests for predicting preterm birth and preeclampsia.
The blood test detects the presence of seven proteins to determine if a patient is likely to respond to the FDA-approved treatment siltuximab.
Multi-Analyte Liquid Biopsy Panel May Aid in Pancreatic Cancer Detection, Staging
The panel's developers at UPenn hope to validate and commercialize a non-invasive assay through a startup called Chip Diagnostics.
Nearly 3,500 patients were referred to the Roberts Individualized Medical Genetics Center for exome sequencing or other testing during the clinical program's first four years.
UPenn researchers believe that their lateral flow assay has the potential to be the first point-of-care test that can detect fentanyl and its metabolite, norfentanyl, at clinically relevant cutoffs.